PERSON
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
F2G Secures $100M Funding for Second Attempt at FDA Approval for Novel Antifungal Drug Olorofim
F2G, antifungal drug, olorofim, FDA approval, funding, second attempt
Adicet Bio Expands into Autoimmune Diseases with Allogeneic Gamma Delta T Cell Therapy
Adicet Bio, Autoimmune diseases, Allogeneic gamma delta T cell therapy, Lupus nephritis, Systemic lupus erythematosus (SLE), Cell therapy
Highlander Health: Revolutionizing Clinical Research with Integrated Solutions
Highlander Health, clinical research, personalized healthcare, evidence generation, technology enablement, Amy Abernethy, Brad Hirsch, Verily, FDA.
AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms
AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study
Candid Therapeutics Launches with $370 Million Funding, Aims to Revolutionize T Cell Engager Market for Autoimmune Diseases
Candid Therapeutics, T Cell Engager, Autoimmune Diseases, Biotech Funding, Ken Song, Pharmaceutical Industry
Eli Lilly Appoints Insider Lucas Montarce as Chief Financial Officer Amid Rising Demand for Weight Loss Drugs
Eli Lilly, Lucas Montarce, CFO, weight loss drugs, Mounjaro, Zepbound, pharmaceutical industry, leadership transition
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck
Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment
Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies
Astellas Gene Therapies to Close South San Francisco Manufacturing Facility
Astellas Gene Therapies, South San Francisco, manufacturing facility closure, gene therapy, biotech layoffs